Asymmetric Hydrogenation of 1-aryl substituted-3,4-Dihydroisoquinolines with Iridium Catalysts Bearing Different Phosphorus-Based Ligands

Giorgio Facchetti [1,*], **Michael S. Christodoulou** [1], **Eleonora Binda** [2], **Marco Fusè** [3] and **Isabella Rimoldi** [1,*]

[1] Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy; michail.christodoulou@unimi.it
[2] Dipartimento di Chimica, Università degli Studi di Milano, via C. Golgi, 19, 20133 Milano, Italy; eleonora.binda@studenti.unimi.it
[3] Scuola Normale Superiore, Piazza dei Cavalieri 7, 56126 Pisa, Italy; marco.fuse@sns.it
[*] Correspondence: giorgio.facchetti@unimi.it (G.F.); isabella.rimoldi@unimi.it (I.R.);

check for updates

Abstract: Starting from the chiral 5,6,7,8-tetrahydroquinolin-8-ol core, a series of amino-phosphorus-based ligands was realized. The so-obtained amino-phosphine ligand (**L1**), amino-phosphinite (**L2**) and amino-phosphite (**L3**) were evaluated in iridium complexes together with the heterobiaryl diphosphines tetraMe-BITIOP (**L4**), Diophep (**L5**) and **L6** and **L7** ligands, characterized by mixed chirality. Their catalytic performance in the asymmetric hydrogenation (AH) of the model substrate 6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinoline **1a** led us to identify Ir-**L4** and Ir-**L5** catalysts as the most effective. The application of these catalytic systems to a library of differently substituted 1-aryl-3,4-dihydroisoquinolines afforded the corresponding products with variable enantioselective levels. The 4-nitrophenyl derivative **3b** was obtained in a complete conversion and with an excellent 94% e.e. using Ir-**L4,** and a good 76% e.e. was achieved in the reduction of 2-nitrophenyl derivative **6a** using Ir-**L5**.

Keywords: atropoisomeric chirality; chiral diphosphines; amino phosphine; imines reduction; iridium complexes

1. Introduction

Many pharmaceutically active compounds owe their physiological activity to the presence of an aminic group in their structure. In particular, 1,2,3,4–tetrahydroquinolines and their analogs are very important building blocks for the synthesis of biologically active compounds [1–3] such as salsolidine [4–7] and carnegine [8], solifenacin [9], cryptostyline [10], complex alkaloids [11–14] and new derivatives active as anti-HIV agents [15] and as anticonvulsants (as an inhibitor of carbonic anhydrase [16] or as a non-competitive antagonist via interaction with the glutamate ionotropic AMPA receptor complex) [17] (Figure 1).

The traditional organic methods for the synthesis of tetrahydroquinoline are based on condensation, the cyclization/reduction sequence and intramolecular nucleophilic addition [18–23]. Many efforts have been made to improve the synthetic approach via catalytic methods [7,24–31]. Considering the convenience in terms of efficiency and atom economy, asymmetric hydrogenation (AH) of prochiral imines, using phosphine-based metal complexes as catalysts, was evinced as the most practical application. It is well known that the steric hindrance of the ligands plays an important role in the

asymmetric reduction of this substrate, and matching the hindrance of both catalyst and substrate could enhance the performance of the asymmetric reduction. Among the very first works in the asymmetric hydrogenation of such a class of substrates [32,33], Zhang's group [28] and Ratovelomanana-Vidal's group [34,35] have made a breakthrough, setting up an innovative strategy for the reduction of dihydroisoquinolines. The atropoisomerism, stemming from a restricted rotation around aryl–aryl bonds, constitutes the structural feature accounting for the selectivity in many diphosphine ligands, both as binaphane-type ligands and as classic chiral ones [36,37]. On the contrary, the amino-monophosphine ligands bearing a 1,1′-bi-2-naphthol as an additional source of chirality have been less studied. In this work, we compared three different types of phosphine ligands bearing an atropoisomeric chirality in iridium (III) complexes for the reduction of substituted cyclic aromatic 1-aryl imines.


Figure 1. Representative bioactive compounds based on tetrahydroquinolines

2. Results and Discussion

Atropoisomerism is a special characteristic that, based on the 1,1′-bi-2-naphthol moiety, furnishes one of the most common and efficient sources of chirality in the pool of phosphine ligands.

Based on our experience in the use of the chiral 8-amino-5,6,7,8-tetrahydroquinoline scaffold and its derivatives as ligands in transition metal complexes, and considering their employment as sources of chirality in organometallic catalysts for asymmetric reduction or for C–B bond formation reactions [38–40], we decided to focus our attention on the synthesis of three amino monophosphine ligands: amino-phosphine (**L1**), -phosphinite (**L2**) [41,42] and -phosphite (**L3**). For the synthesis of amino monophosphines, we started from the chiral 5,6,7,8-tetrahydroquinolin-ol, the enantiomers of which were successfully separated through enzymatic DKR by *Candida antarctica* lipase B with high yield and purity [43]. The synthesis of the three different types of amino monophosphines proceeded as reported in Scheme 1. These ligands were synthesized with the aim of evaluating the importance of the atropoisomeric scaffold when starting from an amino-phosphine in order to afford ligand **L3**, in which the 1,1′-bi-2-naphthol moiety resulted in an additional source of chirality or/and of additional steric hindrance.

In the case of the monophosphine **L1**, the synthesis proceeded without racemization at the chiral center at position 8 of the tetrahydroquinoline, as evinced by chiral HPLC analysis (see SI). These monophosphines were used in comparison with other atropoisomeric phosphines known from the literature, in each of which atropoisomerism assumed peculiar features: in **L4** [44,45] and **L5** [46], the heterobiaryl moiety afforded the core of the diphosphines, introducing an axial chirality element comparable to the one arising from a 1,1′-bi-2-naphthol, although with a different steric hindrance.

Moreover, **L5** provided mixed stereogenic elements similar to **L6** and **L7** [47] in which the ligands comprise one stereogenic sp^3 carbon atom backbone and the stereogenic axis of the biaryl moiety (Table 1).

Scheme 1. Synthesis of 8-(diphenylphosphanyl)-5,6,7,8-tetrahydroquinoline, PN-CAMPY-*R* **L1**, (*R*)-8-((diphenylphosphanyl)oxy)-5,6,7,8-tetrahydroquinoline, OPN-CAMPY-*R* **L2** and (8*R*)-8-(((4*R*)-dinaphtho [2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-yl)oxy)-5,6,7,8-tetrahydroquinoline, OPO$_2$N-CAMPY-*RR$_{ax}$* **L3**.

The catalytic investigation was applied to the asymmetric hydrogenation of a series of synthesized cyclic aromatic 1-aryl imines under different reaction conditions, employing Ir-precatalysts generated in situ. For a preliminary screening, the commercially available 6,7-dimethoxy-1-phenyl-3, 4-dihydroisoquinoline **1a** was used as a model substrate in order to set up the reaction.

Among the variables of the conditions taken into consideration, the ones able to impact the outcome of the reaction included the use of different types of additives (1,3-dichloro-5,5-dimethylhydantoin, DCDMH [48], FeCl$_3$, *N*-bromosuccinimide, NBS, *N*-chlorosuccinimide [32] or H$_3$PO$_4$ [9]) and of the solvent employed (THF, toluene, CH$_2$Cl$_2$) [49] (see SI, Table S1; data refer to substrate **1a**). In the reactions in which **L1**, **L2**, **L3** and **L7** were used as ligands, the presence of an additive proved mandatory (Table 1, entries 1, 3, 5 and 17). From the obtained results, the optimized protocol for the AH reaction comprised a 100/1 substrate/catalyst ratio in toluene under 20 atm of molecular hydrogen in the presence of 10% molar of additive at 20°C for 12 h. Neither the increase in temperature nor a higher hydrogen pressure allowed significant variations to be obtained in terms of enantioselectivity.

The obtained data underlined that the best results in terms of conversion and enantioselectivity were achieved by using NBS as an additive for all ligands (Table 1, entries 2, 4, 6, 9, 11, 13, 16 and 18). Regarding the phosphorous ligands, the amino-monophosphines **L1**-**L3** proved less active, and only modest enantiomeric excesses accompanied the reaction (20–39% e.e., Table 1, entries 2, 4 and 6), although the addition of the 1,1′-bi-2-naphtol moiety in the ligand slightly increased the enantioselectivity (Table 1, entry 6). The same results were obtained in the presence of ligands **L6** and **L7**, in which the mixed types of chirality (sp^3 and axial) did not match (Table 1, entries 16 and 18). The best results were obtained by the classical atropoisomeric diphosphines **L4** and **L5** (Table 1, entries 9 and 13). In particular, in the presence of tetraMe-BITIOP as the ligand, good enantioselectivity was achieved with either NBS or DCDMH as the additive, although the conversion was completed only in the presence of NBS within 12 h (Table 1, entry 7 vs. entry 9). An increase in the substrate/catalyst ratio

to 250/1 did not affect the enantioselectivity of the reaction, with only a minimum erosion in terms of conversion within the settled reaction time (12 h) (Table 1, entry 11).

Table 1. Screening of different iridium complexes bearing **L1–7**.

Entry	Ligand	Additive	Conversion %[b]	e.e. (*S* %) [b]
1	**L1**-*R*	-	-	-
2	**L1**-*R*	NBS	50	20
3	**L2**-*R*	-	-	-
4	**L2**-*R*	NBS	27	32
5	**L3**-*RR*$_{ax}$	-	-	-
6	**L3**-*RR*$_{ax}$	NBS	41	39
7	**L4**-*R*	DCDMH [c]	83	73
8	**L4**-*R*	-	85	50
9	**L4**-*R*	NBS	>99	72
10	**L4**-*R*	FeCl$_3$	85	72
11	**L4**-*R* [a]	NBS	90	71
12	**L5**-*SSS*$_{ax}$	-	10	38
13	**L5**-*SSS*$_{ax}$	NBS	69	55
14	**L6**-*RR*$_{ax}$	-	21	27
15	**L6**-*RR*$_{ax}$	DCDMH	5	25
16	**L6**-*RR*$_{ax}$	NBS	50	25
17	**L7**-*SR*$_{ax}$*R*$_{ax}$	-	-	-
18	**L7**-*SR*$_{ax}$*R*$_{ax}$	NBS	25	25

Reactions were conducted using 1 mol % iridium complex in toluene with or without an additive (catalyst:additive = 1:10) at 20 °C and 20 atm of H$_2$ pressure for 12 h. [a] The reaction was conducted using 0.4 mol % iridium complex. [b] Conversion was determined by ^{1}H-NMR, while enantiomeric excess was determined by HPLC equipped with a chiral column (Chiralcel OD-H). [c] DCDMH = 1,3-dichloro-5,5-dimethyl-hydantoin.

The synthesis of differently substituted derivatives of the standard substrate **1a** was accomplished following the well-known Bischler–Napieralski cyclodehydration [50]. All the obtained products were fully characterized by NMR and MS analysis results in accordance with the data reported in the literature, with the exception of 1-(3,5-bis(trifluoromethyl)phenyl)-3,4-dihydroisoquinoline, **11a**, here reported for the first time to the best of our knowledge. Considering that the best performances were obtained using atropoisomeric diphosphines **L4** and **L5** in situ coordinated with the iridium(III)

metal center (see Table S1 in SI for comparison), the asymmetric hydrogenation of the substrates reported below was carried out under the following optimized reaction conditions established for the standard substrate **1a**: substrate/catalyst ratio of 100/1 (final substrate concentration of 10 mM) in toluene in the presence of 10% molar of NBS as an additive under 20 atm of hydrogen pressure at 20 °C for 12 h. This allowed a comparison of the reactivity of the catalytic systems to be made relative to the structural and electronic differences of the substrates.

As evinced by the data reported in Figure 2, for all the 1-aryl imines, the best results in terms of enantioselectivity and conversion were afforded by using the **L4** ligand, providing an e.e. of up to 94% along with 99% conversion for the substrate **3a**. The only exceptions were obtained in the reduction of 1-phenyl-1,2,3,4-tetrahydroisoquinoline, **8a**, for which **L5** raised the enantiomeric excess to 75% with a good conversion of 86%, and in the reduction of the substrate **6a**, for which a 76% e.e. was reached, although with a modest conversion of 45%. Indeed, the reduction of the substrates **8a-11a**, characterized by the absence of the two methoxy groups on the quinoline ring, confirmed the pivotal role of the p-NO$_2$ group in furnishing enantiodiscrimination in the reaction when Ir-**L4** was used as the catalyst, allowing it to obtain **10b** with 81% e.e. The differences in both enantioselectivity and conversion rate between the two diphosphines could be due to the basicity and, consequently, to the more electron-rich properties of **L4** compared with **L5** and, conversely, to the steric hindrance of **L5**, which is greater than that of **L4**.


Figure 2. Asymmetric hydrogenation of different 1-aryl imines using **L4** and **L5** as ligands.

3. Conclusions

Different types of chiral phosphines serving as a source of chirality in an atropoisomeric moiety due to the presence of axial biaryl asymmetry were evaluated in the reduction of a standard cyclic imine, 6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinoline **1a**. By this preliminary screening, the classical atropoisomeric diphosphines, **L4** and **L5**, proved the most effective ligands in iridium complexes for the asymmetric hydrogenation of this substrate, while the amino-monophosphines **L1**, **L2** and **L3** were less stereoselective as ligands despite the presence of the additional 1,1'-bi-2-naphthol moiety. Th ligands **L6** and **L7**, comprising both the stereogenic sp^3 carbon atom backbone and the stereogenic axis of the biaryl moiety, resulted in poor enantioselectivity. With the optimal reaction conditions in hand, we were able to extend the scope of the reaction to a series of 1-aryl cyclic imines, different from an electronic point of view for the presence of electron-withdrawing or electron-donor groups on the 1-phenyl substituent. An excellent 94% e.e. was achieved in the AH of the substrate **3a** using the Ir-**L4** complex, with a complete conversion for substrate **7a**, although with a lower but still good 71% e.e. A remarkable point is the 82% e.e. reached in the reduction of the steric-hindered imine **5a**. The Ir-catalytic system, [Ir(COD)Cl]$_2$ and the **L5** ligand, afforded the best results in the AH of the 1-(2-nitro)phenyl-substituted substrate **6a** with a 76% e.e. and in the AH of the simple but demanding substrate **8a**, affording the product with a good e.e. of 75% and with 86% conversion.

4. Experimental

General: ^{1}H-, ^{13}C- and ^{31}P-NMR spectra were recorded in CDCl$_3$ or C$_6$D$_6$ on Bruker DRX Avance 400 and 300 MHz equipped with a non-reverse probe. Chemical shifts (in ppm) were referenced to the residual solvent proton/phosphorous peak. MS analyses were performed by using a Thermo Finnigan (MA, USA) LCQ Advantage system MS spectrometer with an electrospray ionization source and an 'Ion Trap' mass analyzer. The MS spectra were obtained by direct infusion of a sample solution in MeOH under ionization, ESI positive. Catalytic reactions were monitored by HPLC analysis with Merck-Hitachi L-7100 equipped with Detector UV6000LP and a chiral column (Chiralcel OD-H, Chiralpak AD, Lux Cellulose-2 or Lux Amylose-2).

4.1. General Procedure for Synthesis of Substrates

The synthesis of substrates was conducted as reported in the literature. To a solution of 2-arylethylamine (1.0 eq.) and triethylamine (1.5 eq.) in CH$_2$Cl$_2$ (40 mL) at 0 °C, carbonyl chloride (1.0 eq.) was slowly added. The mixture was stirred at room temperature overnight, and then it was concentrated in vacuo. EtOAc (30 mL) was added, and the solution was washed with saturated NH$_4$Cl solution (30 mL). The aqueous layer was extracted with EtOAc (3 × 20 mL), and the combined organic layers were washed with brine (50 mL) and dried with anhydrous Na$_2$SO$_4$. The solvent was evaporated, and the residue was used without further purification. To a solution of N-acyl-2-arylethylamine (1.0 eq.) and 2-chloropyridine (1.2 eq.) in CH$_2$Cl$_2$ (25 mL) cooled at −78 °C, trifluoromethanesulfonic anhydride (1.1 eq.) was added dropwise. Then, the mixture was slowly warmed to room temperature and stirred overnight. The reaction was quenched with saturated NaHCO$_3$ solution and extracted with CH$_2$Cl$_2$ (3 × 20 mL). The combined organic layers were washed with brine and dried with anhydrous Na$_2$SO$_4$. After that, the solvent was reduced in vacuo, and the obtained product was purified by flash chromatography (yield: 50–85%). All the obtained substrates were characterized, and the analytical results matched those reported in the literature [25,50–54].

1-(3,5-Bis(trifluoromethyl)phenyl)-3,4-dihydroisoquinoline, (**11a**): pale yellow oil, yield 53%; ^{1}H NMR (300 MHz, CDCl$_3$) δ 8.12 (s, 2H), 7.97 (s, 1H), 7.44 (dt, *J* = 7.5 Hz *J* = 1.2 Hz, 1H), 7.33–7.27 (m, 2H), 7.15 (d, *J* = 7.5 Hz, 1H), 3.94–3.89 (m, 2H), 2.87–82 (m, 2H) ppm; ^{13}C NMR (75 MHz, CDCl$_3$) δ: 164.9, 141.0, 138.8, 131.6 (q, $^2J_{CF}$ = 33 Hz, 2C), 131.4, 129.0 (q, $^3J_{CF}$ = 3.0 Hz, 2C), 127.9, 127.7, 127.0, 126.9, 126.8 (q, $^1J_{CF}$ = 273 Hz, 2C), 123.0 (q, $^3J_{CF}$ = 3.8 Hz), 47.9, 26.0 ppm. FTIR (NaCl) *ν* = 3072.04, 2941.10, 1624.11,

1609.56, 1389.17, 1278.13, 1183.71, 1128.18, 890.92, 745.80 cm^{-1}; MS (ESI) for $C_{17}H_{11}F_6N$: *m/z* 344.01 [M+H]$^+$.

4.2. Synthesis of (R)-8-(Diphenylphosphanyl)-5,6,7,8-Tetrahydroquinoline, L1

The chiral 5,6,7,8-tetrahydroquinoline-8-ol was obtained as previously reported with a yield of 89% for the (*R*)-enantiomer (99% e.e.) and 87% for the (*S*)-enantiomer (96% e.e.) [43]. To a solution of (*S*)-5,6,7,8-tetrahydroquinoline-8-ol (1 mmol) in 5 mL of anhydrous THF at 0 °C, TEA (2.5 eq.) was added. Methanesulfonyl chloride (1.5 eq.) was added dropwise, and the mixture was stirred at 0 °C for 10 min. The temperature was decreased to −78 °C, and potassium diphenylphosphide solution (0.5 M) in THF (1.7 eq.) was added within 15 min. The mixture was stirred for 6 h, and the temperature was warmed to room temperature. At the end of the reaction, 5 mL of diethyl ether and HCl (2M) was added until the solution reached an acid pH. The organic phase was extracted with 3 × 5 mL of diethyl ether and washed with a saturated solution of Na_2CO_3 until it reached a basic pH. The aqueous phase was extracted with dichloromethane (3 × 5 mL). Combined organic layers were dried over Na_2SO_4, and the solvent was evaporated. The obtained product did not need further purification. ^{1}H-NMR (CDCl$_3$, 400 MHz) δ: 8.23 (d, J = 3.9 Hz, 1H), 7.53–7.21 (m, 11H), 6.99–6.95 (m, 1H), 3.93–3.88 (m, 1H), 2.75 (t, J = 6.0 Hz, 2H), 2.08–1.98 (m, 1H), 1.90–1.77 (m, 2H), 1.73–1.62 (m, 1H) ppm; ^{13}C NMR (100 MHz, CDCl$_3$) δ 158.6, 147.3, 137.0, 135.1, 134.8, 134.2 (2C), 133.9 (2C), 129.4, 129.0 (2C), 128.9 (2C), 128.4 (2C), 121.6, 41.7, 29.1, 26.8, 22.2 ppm; ^{31}P-NMR (CDCl$_3$, 160 MHz): δ 2.76 ppm; MS (ESI) for $C_{21}H_{20}NP$: *m/z* 318.23 [M+H]$^+$.

4.3. Synthesis of (R)-8-((Diphenylphosphanyl)oxy)-5,6,7,8-Tetrahydroquinoline and (8R)-8-(((4R)-Dinaphtho [2,1-d:1′,2′-f][1,3,2]Dioxaphosphepin-4-yl)oxy)-5,6,7,8-Tetrahydroquinoline, L2 and L3

The chiral 5,6,7,8-tetrahydroquinolin-8-ol and (*R*)-(+)-1,1′-binaphthyl-2,2′-diylphosphite chloride were obtained as previously reported. To a solution of NaH (1.1 eq.) in 5 mL of anhydrous THF at 0 °C was added (*S*)-5,6,7,8-tetrahydroquinolin-8-ol (1 mmol). The suspension was stirred for 30 min, and chlorodiphenylphosphine or (*R*)-(+)-1.1′-binaphthyl-2,2′-diylphosphite chloride (1.1 eq.) was added. The mixture was then stirred at room temperature for 1 h. Then, 10 mL of diisopropyl ether was added, and the formed precipitate, containing the inorganic salts, was filtered off. The solvent was evaporated, and the obtained white solid did not need further purification.

L2: ^{1}H-NMR (C$_6$D$_6$, 400 MHz) δ: 8.30 (d, J = 4.4 Hz, 1H), 7.78–7.63 (m, 2H), 7.50–7.10 (m, 10H), 4.74 (t, J = 5.2 Hz, 1H), 2.76–2.65 (m, 2H), 2.16–1.68 (m, 4H) ppm; ^{13}C NMR (100 MHz, CDCl$_3$) δ 152.6, 146.3, 137.0, 133.4, 132.8, 134.6, 131.8 (4C), 131.2 (2C), 128.7 (2C), 127.8 (2C), 121.9, 43.2, 28.4, 23.8, 20.7 ppm; ^{31}P-NMR (C$_6$D$_6$, 160 MHz): δ 111.4 ppm; MS (ESI) for $C_{21}H_{20}NOP$ *m/z* 334.43 [M+H]$^+$.

L3: ^{1}H-NMR (C$_6$D$_6$, 400 MHz) δ: 7.96–7.02 (m, 14H), 6.84 (d, J = 8.4 Hz, 1H), 4.92 (m, 1H), 2.72–2.61 (m, 3H), 2.28–2.23 (m, 1H), 1.92–1.89 (m, 2H) ppm; ^{13}C NMR (100 MHz, CDCl$_3$) δ 154.0, 150.1 (2C), 145.3, 137.6, 134.6, 134.1, 133.7, 132.8, 131.8, 128.8 (2C), 128.4 (2C), 128.0 (2C), 127.7 (2C), 124.1 (2C), 123.2 (2C), 121.7, 117.9 (2C), 43.3, 28.8, 24.1, 20.8 ppm; ^{31}P-NMR (C$_6$D$_6$, 160 MHz): δ 145.3 ppm; MS (ESI) for $C_{29}H_{22}NO_3P$: *m/z* 464.57 [M+H]$^+$.

4.4. General Procedure for Asymmetric Hydrogenation

[Ir(COD)Cl]$_2$ (0.5 eq.) was added to a solution of phosphine (1 eq.) in 5 mL of solvent, and the mixture was stirred at room temperature for 15 min. The additive (10 eq.) was added and, after stirring for an additional 15 min, the imine (100 eq.) was added to the reaction mixture. The solution was transferred to a stainless-steel autoclave (50 mL) with a cannula. The autoclave, equipped with temperature control and magnetic stirrer, was purged five times with hydrogen and then pressurized at 20 atm, and the temperature was set to 20 °C. At the end, the autoclave was vented, and the mixture was analyzed by HPLC equipped with a chiral column (for analytical conditions, see below).

4.5. Analytical Conditions

The products were analyzed by ^{1}H NMR to determine the molar conversion, whereas the enantiomeric excess was evaluated by HPLC analysis, and the absolute configuration was assigned by comparison with literature references [25,55].

6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline **1b** [25]: *R*-isomer: 12.1 min (*min*); *S*-isomer: 17.3 min (*maj*); column: Chiralcel OD-H, eluent: 2-propanol/hexane = 30/70 (0.01% DEA), flow = 0.7 mL/min, λ = 220 nm.

1-(4-Fluorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline **2b** [25]: *R*-isomer: 21.0 min (*min*); *S*-isomer: 23.9 min (*maj*); column: Chiralpak AD, eluent: 2-propanol/hexane = 10/90, flow = 0.8 mL/min, λ = 220 nm.

6,7-Dimethoxy-1-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline **3b** [54]: *R*-isomer: 25.7 min (*min*); *S*-isomer: 32.5 min (*maj*); column: Chiralcel OD-H, eluent: 2-propanol/hexane = 30/70 (0.01% DEA), flow = 0.7 mL/min, λ = 285 nm.

1-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline **4b** [25]: *R*-isomer: 23.7 min (*min*); *S*-isomer: 33.0 min (*maj*); column: Chiralcel OD-H, eluent: 2-propanol/hexane = 30/70 (0.01% DEA), flow = 0.7 mL/min, λ = 285 nm.

6,7-Dimethoxy-1-(naphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline **5b** [35]: 1 isomer: 14.7 min (*min*); 2 isomer: 16.4 min (*maj*); column: Chiralcel OD-H, eluent: 2-propanol/hexane = 30/70 (0.01% DEA), flow = 0.7 mL/min, λ = 285 nm.

6,7-Dimethoxy-1-(2-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline **6b** [24]: 1 isomer: 8.6 min (*min*); 2 isomer: 15.0 min (*maj*); column: Chiralcel OD-H, eluent: 2-propanol/hexane = 30/70 (0.01% DEA), flow = 0.7 mL/min, λ = 240 nm.

1-(3,5-Bis(trifluoromethyl)phenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline **7b** [56]: 1 isomer: 7.5 min (*maj*); 2 isomer: 8.5 min (*min*); column: Lux Amilose-2, eluent: 2-propanol/hexane = 10/90 (0.01% DEA), flow = 0.8 mL/min, λ = 220 nm.

1-Phenyl-1,2,3,4-tetrahydroisoquinoline **8b** [25]: *S*-isomer: 13.1 (*min*); *R*-isomer: 15.4 (*maj*); column: Chiralpak AD, eluent: 2-propanol/hexane = 4/96, flow = 0.8 mL/min, λ = 240 nm.

1-(4-Fluorophenyl)-1,2,3,4-tetrahydroisoquinoline **9b** [25]: *S*-isomer: 5.5 (*min*); *R*-isomer: 7.1 (*maj*); column: Lux Amylose-2, eluent: 2-propanol/hexane = 10/90, flow = 1.0 mL/min, λ = 220 nm.

1-(4-Nitrophenyl)-1,2,3,4-tetrahydroisoquinoline **10b** [26]: *S*-isomer: 15.9 (*min*); *R*-isomer: 20.9 (*maj*); column: Lux Amylose-2, eluent: 2-propanol/hexane = 10/90 (0.01% DEA), fl ow = 0.8 mL/min, λ = 254 nm.

1-(3,5-Bis(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (**11b**): yellow solid, yield 61 %; ^{1}H NMR (300 MHz, CDCl$_3$) δ: 7.84 (s, 1H), 7.80 (s, 2H), 7.36–7.32 (m, 1H), 7.20–7.21 (m, 2H), 7.12–07 (m, 1H), 5.25 (s, 1H), 3.20–3.13 (m, 2H), 2.91–2.82 (m, 2H) ppm; ^{13}C NMR (75 MHz, CDCl$_3$) δ: 147.9, 136.8, 135.9, 132.0 (q, $^2J_{CF}$ = 33 Hz, 2C), 129.9, 129.6 (q, $^3J_{CF}$ = 3.3 Hz, 2C), 128.1, 127.4, 126.4, 123.3 (q, $^1J_{CF}$ = 273 Hz, 2C), 121.9 (q, $^3J_{CF}$ = 3.8 Hz), 61.8, 42.7, 29.9 ppm. FTIR (NaCl) ν = 3035.13, 2901.08, 1571.24, 1350.12, 1228.89, 1165.04, 1153.73, 873.20, 778.63 cm^{-1}; MS (ESI) for C$_{17}$H$_{13}$F$_6$N: *m/z* 346.21 [M+H]$^+$. HPLC: 1 isomer: 8.2(*min*); 2 isomer: 12.0 (*maj*); column: Lux Cellulose-2, eluent: 2-propanol/hexane = 5/110, flow = 0.6 mL/min, λ = 220 nm.

References

1. Scott, J.D.; Williams, R.M. Chemistry and Biology of the Tetrahydroisoquinoline Antitumor Antibiotics. *Chem. Rev.* **2002**, *102*, 1669–1730. [CrossRef] [PubMed]

2. Abe, K.; Saitoh, T.; Horiguchi, Y.; Utsunomiya, I.; Taguchi, K. Synthesis and Neurotoxicity of Tetrahydroisoquinoline Derivatives for Studying Parkinson's Disease. *Biol. Pharm. Bull.* **2005**, *28*, 1355–1362. [CrossRef] [PubMed]

3. Lin, H.R.; Safo, M.K.; Abraham, D.J. Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2581–2589. [CrossRef] [PubMed]

4. Quinto, T.; Schwizer, F.; Zimbron, J.M.; Morina, A.; Köhler, V.; Ward, T.R. Expanding the Chemical Diversity in Artificial Imine Reductases Based on the Biotin-Streptavidin Technology. *ChemCatChem* **2014**, *6*, 1010–1014. [CrossRef]

5. Noyori, R.; Ohta, M.; Hsiao, Y.; Kitamura, M.; Ohta, T.; Takaya, H. Asymmetric synthesis of isoquinoline alkaloids by homogeneous catalysis. *J. Am. Chem. Soc.* **1986**, *108*, 7117–7119. [CrossRef]

6. Schwizer, F.; Okamoto, Y.; Heinisch, T.; Gu, Y.; Pellizzoni, M.M.; Lebrun, V.; Reuter, R.; Köhler, V.; Lewis, J.C.; Ward, T.R. Artificial Metalloenzymes: Reaction Scope and Optimization Strategies. *Chem. Rev.* **2018**, *118*, 142–231. [CrossRef]

7. Facchetti, G.; Rimoldi, I. 8-Amino-5,6,7,8-tetrahydroquinoline in iridium(iii) biotinylated Cp* complex as artificial imine reductase. *New J. Chem.* **2018**, *42*, 18773–18776. [CrossRef]

8. Pyne, S.G.; Bloem, P.; Chapman, S.L.; Dixon, C.E.; Griffith, R. Chiral sulfur compounds. 9. Stereochemistry of the intermolecular and intramolecular conjugate additions of amines and anions to chiral (E)- and (Z)-vinyl sulfoxides. Total syntheses of (R)-(+)-carnegine and (+)- and (-)-sedamine. *J. Org. Chem.* **1990**, *55*, 1086–1093. [CrossRef]

9. Ružič, M.; Pečavar, A.; Prudič, D.; Kralj, D.; Scriban, C.; Zanotti-Gerosa, A. The Development of an Asymmetric Hydrogenation Process for the Preparation of Solifenacin. *Org. Process Res. Dev* **2012**, *16*, 1293–1300. [CrossRef]

10. Zhu, R.; Xu, Z.; Ding, W.; Liu, S.; Shi, X.; Lu, X. Efficient and Practical Syntheses of Enantiomerically Pure (S)-(−)-Norcryptostyline I, (S)-(−)-Norcryptostyline II, (R)-(+)-Salsolidine and (S)-(−)-Norlaudanosine via a Resolution-Racemization Method. *Chin. J. Chem.* **2014**, *32*, 1039–1048. [CrossRef]

11. Zhurakulov, S.N.; Babkin, V.A.; Chernyak, E.I.; Morozov, S.V.; Grigor'ev, I.A.; Levkovich, M.G.; Vinogradova, V.I. Aminomethylation of 1-Aryl-6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinolines by Dihydroquercetin. *Chem. Nat. Compd.* **2015**, *51*, 57–61. [CrossRef]

12. Guranova, N.I.; Varlamov, A.V.; Novikov, R.A.; Aksenov, A.V.; Borisova, T.N.; Sorokina, E.A.; Voskressensky, L.G. Reaction of benzyne with 1,2,3,4-tetrahydroisoquinolines as an access to 1H-3-benzazepines. *Mendeleev Commun.* **2018**, *28*, 22–24. [CrossRef]

13. Chrzanowska, M.; Rozwadowska, M.D. Asymmetric Synthesis of Isoquinoline Alkaloids. *Chem. Rev.* **2004**, *104*, 3341–3370. [CrossRef] [PubMed]

14. Bentley, K.W. β-Phenylethylamines and the isoquinoline alkaloids. *Nat. Prod. Rep.* **2006**, *23*, 444–463. [CrossRef] [PubMed]

15. Cheng, P.; Huang, N.; Jiang, Z.-Y.; Zhang, Q.; Zheng, Y.T.; Chen, J.J.; Zhang, X.M.; Ma, Y.B. 1-Aryl-tetrahydroisoquinoline analogs as active anti-HIV agents in vitro. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2475–2478. [CrossRef]

16. Bruno, E.; Buemi, M.R.; De Luca, L.; Ferro, S.; Monforte, A.M.; Supuran, C.T.; Vullo, D.; De Sarro, G.; Russo, E.; Gitto, R. In Vivo Evaluation of Selective Carbonic Anhydrase Inhibitors as Potential Anticonvulsant Agents. *ChemMedChem* **2016**, *11*, 1812–1818. [CrossRef]

17. Gitto, R.; Ferro, S.; Agnello, S.; De Luca, L.; De Sarro, G.; Russo, E.; Vullo, D.; Supuran, C.T.; Chimirri, A. Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides. *Bioorg. Med. Chem.* **2009**, *17*, 3659–3664. [CrossRef]

18. Singh, K.N.; Singh, P.; Kaur, M.; Sharma, E. Intermolecular Nucleophilic Addition of N-Diaminophosphinoyl-Protected α-Carbanions Derived from Secondary Amines to Arynes: Synthesis of 1-Aryl-1,2,3,4-tetrahydroisoquinolines. *ChemistrySelect* **2017**, *2*, 2213–2218. [CrossRef]

19. Pesnot, T.; Gershater, M.C.; Ward, J.M.; Hailes, H.C. Phosphate mediated biomimetic synthesis of tetrahydroisoquinoline alkaloids. *Chem. Commun.* **2011**, *47*, 3242–3244. [CrossRef]

20. Vanden Eynden, M.J.; Kunchithapatham, K.; Stambuli, J.P. Calcium-Promoted Pictet-Spengler Reactions of Ketones and Aldehydes. *J. Org. Chem.* **2010**, *75*, 8542–8549. [CrossRef]

21. Vanden Eynden, M.J.; Stambuli, J.P. Calcium-Catalyzed Pictet–Spengler Reactions. *Org. Lett.* **2008**, *10*, 5289–5291. [CrossRef] [PubMed]

22. Doi, S.; Shirai, N.; Sato, Y. Abnormal products in the Bischler–Napieralski isoquinoline synthesis. *J. Chem. Soc. Perkin Trans. 1* **1997**, *15*, 2217–2221. [CrossRef]

23. Paul, A.; Adili, A.; Seidel, D. Redox-Annulations of Cyclic Amines with Electron-Deficient o-Tolualdehydes. *Org. Lett.* **2019**, *21*, 1845–1848. [CrossRef] [PubMed]

24. Vedejs, E.; Trapencieris, P.; Suna, E. Substituted Isoquinolines by Noyori Transfer Hydrogenation: Enantioselective Synthesis of Chiral Diamines Containing an Aniline Subunit. *J. Org. Chem.* **1999**, *64*, 6724–6729. [CrossRef] [PubMed]

25. Nie, H.; Zhu, Y.; Hu, X.; Wei, Z.; Yao, L.; Zhou, G.; Wang, P.; Jiang, R.; Zhang, S. Josiphos-Type Binaphane Ligands for Iridium-Catalyzed Enantioselective Hydrogenation of 1-Aryl-Substituted Dihydroisoquinolines. *Org. Lett.* **2019**, *21*, 8641–8645. [CrossRef]

26. Václavíková, B.; Budinská, A.; Václavík, J.; Matoušek, V.; Kuzma, M.; Červený, L. Asymmetric Transfer Hydrogenation of 1-Aryl-3,4-Dihydroisoquinolines Using a Cp*Ir(TsDPEN) Complex. *Eur. J. Org. Chem.* **2017**, *2017*, 5131–5134. [CrossRef]

27. Lu, S.M.; Wang, Y.Q.; Han, X.W.; Zhou, Y.G. Asymmetric hydrogenation of quinolines and isoquinolines activated by chloroformates. *Angew Chem. Int. Ed. Engl.* **2006**, *118*, 2318–2321. [CrossRef]

28. Chang, M.; Li, W.; Zhang, X. A Highly Efficient and Enantioselective Access to Tetrahydroisoquinoline Alkaloids: Asymmetric Hydrogenation with an Iridium Catalyst. *Angew. Chem. Int. Ed.* **2011**, *50*, 10679–10681. [CrossRef]

29. Shi, L.; Ye, Z.S.; Cao, L.L.; Guo, R.N.; Hu, Y.; Zhou, Y.G. Enantioselective Iridium-Catalyzed Hydrogenation of 3,4-Disubstituted Isoquinolines. *Angew. Chem. Int. Ed.* **2012**, *51*, 8286–8289. [CrossRef]

30. Wen, J.; Tan, R.; Liu, S.; Zhao, Q.; Zhang, X. Strong Bronsted acid promoted asymmetric hydrogenation of isoquinolines and quinolines catalyzed by a Rh-thiourea chiral phosphine complex via anion binding. *Chem. Sci.* **2016**, *7*, 3047–3051. [CrossRef]

31. Schwenk, R.; Togni, A. P-Trifluoromethyl ligands derived from Josiphos in the Ir-catalysed hydrogenation of 3,4-dihydroisoquinoline hydrochlorides. *Dalton Trans.* **2015**, *44*, 19566–19575. [CrossRef] [PubMed]

32. Ji, Y.; Wang, J.; Chen, M.; Shi, L.; Zhou, Y. Dual Stereocontrol for Enantioselective Hydrogenation of Dihydroisoquinolines Induced by Tuning the Amount of N-Bromosuccinimide. *Chin. J. Chem.* **2018**, *36*, 139–142. [CrossRef]

33. Chen, M.; Ji, Y.; Shi, L.; Sun, L.; Zhou, Y. A Method Catalyzed by Iridium and Used for Bidirectional Enantioselective Synthesis of Chiral Tetrahydroisoquinoline. CN107540606 A, 2018.

34. Berhal, F.; Wu, Z.; Zhang, Z.; Ayad, T.; Ratovelomanana-Vidal, V. Enantioselective Synthesis of 1-Aryl-tetrahydroisoquinolines through Iridium Catalyzed Asymmetric Hydrogenation. *Org. Lett.* **2012**, *14*, 3308–3311. [CrossRef]

35. Perez, M.; Wu, Z.; Scalone, M.; Ayad, T.; Ratovelomanana-Vidal, V. Enantioselective Synthesis of 1-Aryl-Substituted Tetrahydroisoquinolines Through Ru-Catalyzed Asymmetric Transfer Hydrogenation. *Eur. J. Org. Chem.* **2015**, *2015*, 6503–6514. [CrossRef]

36. Fusè, M.; Rimoldi, I.; Cesarotti, E.; Rampino, S.; Barone, V. On the relation between carbonyl stretching frequencies and the donor power of chelating diphosphines in nickel dicarbonyl complexes. *Phys. Chem. Chem. Phys.* **2017**, *19*, 9028–9038. [CrossRef]

37. Fusè, M.; Rimoldi, I.; Facchetti, G.; Rampino, S.; Barone, V. Exploiting coordination geometry to selectively predict the σ-donor and π-acceptor abilities of ligands: A back-and-forth journey between electronic properties and spectroscopy. *Chem. Commun.* **2018**, *54*, 2397–2400. [CrossRef]

38. Rimoldi, I.; Facchetti, G.; Cesarotti, E.; Pellizzoni, M.; Fuse, M.; Zerla, D. Enantioselective transfer hydrogenation of aryl ketones: Synthesis and 2D-NMR characterization of new 8-amino-5,6,7,8-tetrahydroquinoline Ru(II)-complexes. *Curr. Org. Chem.* **2012**, *16*, 2982–2988. [CrossRef]

39. Gandolfi, R.; Facchetti, G.; Christodoulou, M.S.; Fusè, M.; Meneghetti, F.; Rimoldi, I. Cascade Reaction by Chemo and Biocatalytic Approaches to Obtain Chiral Hydroxy Ketones and anti 1,3–Diols. *ChemistryOpen* **2018**, *7*, 393–400. [CrossRef]

40. Facchetti, G.; Ferri, N.; Lupo, M.G.; Giorgio, L.; Rimoldi, I. Monofunctional PtII Complexes Based on 8-Aminoquinoline: Synthesis and Pharmacological Characterization. *Eur. J. Inorg. Chem.* **2019**, *2019*, 3389–3395. [CrossRef]

41. Kaiser, S.; Smidt, S.P.; Pfaltz, A. Iridium Catalysts with Bicyclic Pyridine–Phosphinite Ligands: Asymmetric Hydrogenation of Olefins and Furan Derivatives. *Angew. Chem. Int. Ed.* **2006**, *45*, 5194–5197. [CrossRef] [PubMed]

42. Liu, Q.B.; Yu, C.B.; Zhou, Y.G. Synthesis of tunable phosphinite–pyridine ligands and their applications in asymmetric hydrogenation. *Tetrahedron Lett.* **2006**, *47*, 4733–4736. [CrossRef]

43. Uenishi, J.; Hamada, M. Synthesis of Enantiomerically Pure 8-Substituted 5,6,7,8-Tetrahydroquinolines. *Synthesis* **2002**, *2002*, 0625–0630. [CrossRef]

44. Benincori, T.; Brenna, E.; Sannicolò, F.; Trimarco, L.; Antognazza, P.; Cesarotti, E.; Demartin, F.; Pilati, T. New Class of Chiral Diphosphine Ligands for Highly Efficient Transition Metal-Catalyzed Stereoselective Reactions: The Bis(diphenylphosphino) Five-membered Biheteroaryls. *J. Org. Chem.* **1996**, *61*, 6244–6251. [CrossRef]

45. Facchetti, G.; Cesarotti, E.; Pellizzoni, M.; Zerla, D.; Rimoldi, I. "In situ" Activation of Racemic RuII Complexes: Separation of trans and cis Species and Their Application in Asymmetric Reduction. *Eur. J. Inorg. Chem.* **2012**, *2012*, 4365–4370. [CrossRef]

46. Cesarotti, E.; Abbiati, G.; Rossi, E.; Spalluto, P.; Rimoldi, I. DIOPHEP, a chiral diastereoisomeric bisphosphine ligand: Synthesis and applications in asymmetric hydrogenations. *Tetrahedron* **2008**, *19*, 1654–1659. [CrossRef]

47. Cesarotti, E.; Araneo, S.; Rimoldi, I.; Tassi, S. Aminophosphonite-phosphite and aminophosphonite-phosphinite ligands with mixed chirality: Preparation and catalytic applications in asymmetric hydrogenation and hydroformylation. *J. Mol. Catal. A* **2003**, *204-205*, 211–220. [CrossRef]

48. Facchetti, G.; Bucci, R.; Fusè, M.; Rimoldi, I. Asymmetric Hydrogenation vs Transfer Hydrogenation in the Reduction of Cyclic Imines. *ChemistrySelect* **2018**, *3*, 8797–8800. [CrossRef]

49. Zhang, D.; Zhou, X.; Liu, R.; Li, M.; Li, X.; Jiang, R.; Nie, H.; Zhang, S. Josiphos-type binaphane ligands for the asymmetric Ir-catalyzed hydrogenation of acyclic aromatic N-aryl imines. *Catal. Commun.* **2020**, *136*, 105906. [CrossRef]

50. Min, L.; Yang, W.; Weng, Y.; Zheng, W.; Wang, X.; Hu, Y. A Method for Bischler–Napieralski-Type Synthesis of 3,4-Dihydroisoquinolines. *Org. Lett.* **2019**, *21*, 2574–2577. [CrossRef]

51. Zhang, R.; Qin, Y.; Zhang, L.; Luo, S. Mechanistic Studies on Bioinspired Aerobic C–H Oxidation of Amines with an ortho-Quinone Catalyst. *J. Org. Chem.* **2019**, *84*, 2542–2555. [CrossRef] [PubMed]

52. Wu, Y.; Yi, H.; Lei, A. Electrochemical Acceptorless Dehydrogenation of N-Heterocycles Utilizing TEMPO as Organo-Electrocatalyst. *ACS Catal.* **2018**, *8*, 1192–1196. [CrossRef]

53. Zheng, B.; Trieu, T.H.; Li, F.L.; Zhu, X.L.; He, Y.G.; Fan, Q.Q.; Shi, X.X. Copper-Catalyzed Benign and Efficient Oxidation of Tetrahydroisoquinolines and Dihydroisoquinolines Using Air as a Clean Oxidant. *ACS Omega* **2018**, *3*, 8243–8252. [CrossRef] [PubMed]

54. Lucena-Serrano, C.; Lucena-Serrano, A.; Rivera, A.; López-Romero, J.M.; Valpuesta, M.; Díaz, A. Synthesis and dopaminergic activity of a series of new 1-aryl tetrahydroisoquinolines and 2-substituted 1-aryl-3-tetrahydrobenzazepines. *Bioorg. Chem.* **2018**, *80*, 480–491. [CrossRef] [PubMed]

55. Chen, M.W.; Ji, Y.; Wang, J.; Chen, Q.A.; Shi, L.; Zhou, Y.G. Asymmetric Hydrogenation of Isoquinolines and Pyridines Using Hydrogen Halide Generated in Situ as Activator. *Org. Lett.* **2017**, *19*, 4988–4991. [CrossRef] [PubMed]

56. Hati, S.; Sen, S. Cerium Chloride Catalyzed, 2-Iodoxybenzoic Acid Mediated Oxidative Dehydrogenation of Multiple Heterocycles at Room Temperature. *Eur. J. Org. Chem.* **2017**, *2017*, 1277–1280. [CrossRef]